Renal tubular acidosis primary prevention: Difference between revisions
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} ;{{AE}} {{ADG}} | {{CMG}} ;{{AE}} {{ADG}} | ||
==Overview== | ==Overview== | ||
There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes regulation of the use of medications responsible in high-risk groups with caution. | |||
==Primary Prevention== | ==Primary Prevention== | ||
There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes: | There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes: | ||
Latest revision as of 13:01, 1 June 2018
|
Renal tubular acidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Renal tubular acidosis primary prevention On the Web |
|
American Roentgen Ray Society Images of Renal tubular acidosis primary prevention |
|
Risk calculators and risk factors for Renal tubular acidosis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes regulation of the use of medications responsible in high-risk groups with caution.
Primary Prevention
There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes:
- Regulation of the use of both lead and cadmium exposure in high-risk groups with caution.
- Changes in tetracycline manufacture.
- Use of cisplatin at lower dose levels.
- Avoidance of the offending agents in patients with hereditary sensitivity to particular carbohydrates.